Dr. Salman Bhai joins MSU to share best practices related to myositis care and empowers you to seek the...
The goal of this webinar is to inform you about best practices as related to myositis care and empower...
Orphazyme's Arimoclomol receives US Fast Track designation in sporadic Inclusion Body Myositis, an incurable rare progressively debilitating muscle-wasting disease...
An Update on the Clinical Studies Using Arimoclomol as a Potential Treatment for Sporadic Inclusion Body Myositis VideoMyositis Support, , Featured, Inclusion Body Myositis (IBM)
The ongoing Arimoclomol Clinical Trial for sIBM continues to generate a lot of questions from our community. As part...
Identification of Predictors for Interstitial Lung Disease in Myositis Patients: A Systematic ReviewMyositis Support, , Featured, Myositis, News
Interstitial lung disease (ILD) is a well-recognized complication in the spectrum of diseases known as the idiopathic inflammatory myopathies...
The first step when approaching a patient with muscle weakness – Differential diagnosis of idiopathic inflammatory myopathies in adultsMyositis Support, , Featured, Myositis
Information on the differential diagnosis of adults with muscle weakness. Differential diagnosis is the process of distinguishing a specific...
Choose your language
- Explore Myositis
- Financial Assistance Program
- #ItsMyTurn: Becoming a Plasma Donor Hero
- Myositis Clinical Trials
- Myositis Empower Walk
- Myositis Webinars
- The Grieving Project
- Upcoming Events
- Donate today!